Literature DB >> 4147189

On the mechanism of L-dopa-induced postural hypotension in the cat.

K M Dhasmana, B A Spilker.   

Abstract

1. The effects of L-DOPA on postural hypotension and carotid occlusion pressor effect were studied, mainly in cats; the recovery of the blood pressure upon tilting was used as a measure of postural hypotension.2. L-DOPA (30 mg/kg) partially depressed the carotid occlusion pressor effect and caused some degree of postural hypotension, L-DOPA (100 mg/kg) had more marked effects; the responses returned to control after 90 to 150 minutes. L-DOPA itself caused a pressor response in all cats.3. The dopa decarboxylase inhibitor N(1)-(DL-seryl)-N(2)-(2,3,4-trihydroxybenzyl) hydrazine (RO4-4602, 50 and 10 mg/kg) had no effect itself on the tilt response but completely prevented the effects of L-DOPA on the carotid occlusion pressor effect and postural hypotension.4. After RO4-4602 (3 and 1 mg/kg), L-DOPA (100 mg/kg) caused a brief rise of blood pressure followed by a longer lasting fall in horizontally-orientated cats (i.e. ;supine' hypotension). No postural hypotension was observed after L-DOPA under these conditions.5. Noradrenaline elicited only small and transient effects on postural hypotension, but dopamine's effects were more marked and longer lasting. Pressor dose-response relationships for noradrenaline were the same before and after L-DOPA, as well as in cats pretreated with L-DOPA for 4 days.6. In cats with kidneys and intestines removed, the tilt reflex was still present. Dose-response curves to L-DOPA were the same as in normal animals. RO4-4602 (3 mg/kg) prevented postural hypotension and block of the carotid occlusion pressor effect; supine hypotension was also observed after L-DOPA.7. The recovery response to tilting in spinal cats was markedly depressed or absent unless the blood pressure was elevated by angiotensin, in which experiments L-DOPA depressed the recovery upon tilting (i.e. induced postural hypotension).8. Blood pressure responses to tyramine were increased after 10 mg/kg of L-DOPA, but depressed after 100 mg/kg. The response to tyramine was not depressed, however, when RO4-4602 was given to block the dopa-dopamine conversion.9. The response to sympathetic stimulation in pithed rats was depressed after L-DOPA and dopamine, but not after alpha-methyldopa.10. alpha-Methyldopa (300 mg/kg) given acutely caused a moderate degree of postural hypotension and a more marked postural hypotension if given for two days.11. It is concluded that it is possible to differentiate between the supine and postural hypotension caused by L-DOPA and that supine hypotension is due to a central effect and postural hypotension to an extracerebral effect. Postural hypotension is discussed in relation to six hypotheses presented to explain its effect. Postural hypotension after L-DOPA is probably not due to a-adrenoceptor blockade, a central effect or any effect on the kidney. The most likely hypothesis is that L-DOPA forms dopamine which acts as a false transmitter in the peripheral sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4147189      PMCID: PMC1776322          DOI: 10.1111/j.1476-5381.1973.tb08175.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  EFFECT OF DOPAMINE IN MAN: AUGMENTATION OF SODIUM EXCRETION, GLOMERULAR FILTRATION RATE, AND RENAL PLASMA FLOW.

Authors:  R H MCDONALD; L I GOLDBERG; J L MCNAY; E P TUTTLE
Journal:  J Clin Invest       Date:  1964-06       Impact factor: 14.808

2.  Impairment of sympathetic nerve responses by dopa, dopamine and their alpha-methyl analogues.

Authors:  J B Farmer
Journal:  J Pharm Pharmacol       Date:  1965-10       Impact factor: 3.765

3.  Comparative investigation of inhibitors of extracerebral dopa decarboxylase in man and rats.

Authors:  I Kuruma; G Bartholini; R Tissot; A Fletscher
Journal:  J Pharm Pharmacol       Date:  1972-04       Impact factor: 3.765

4.  Action of L- -methyldopa-hydrazine on the blood pressure of patients receiving levodopa.

Authors:  D B Calne; A Petrie; S Rao; J L Reid; S D Vakil
Journal:  Br J Pharmacol       Date:  1972-01       Impact factor: 8.739

5.  Comparison of carotid artery occlusion and tilt responses in dogs.

Authors:  J W Constantine; W K McShane; S C Wang
Journal:  Am J Physiol       Date:  1971-12

6.  Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.

Authors:  A M Watanabe; T N Chase; P V Cardon
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

7.  Alterations in tyrosine hydroxylase and monoamine oxidase activity in blood vessels.

Authors:  J Tarver; B Berkowitz; S Spector
Journal:  Nat New Biol       Date:  1971-06-23

8.  Chronic dopa treatment: effect on the concentration of norepinephrine in the hearts and brains of rats.

Authors:  G R Breese; A J Prange
Journal:  Eur J Pharmacol       Date:  1971-01       Impact factor: 4.432

9.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

10.  Selective rise in brain dopamine by inhibition of extracerebral levodopa decarboxylation.

Authors:  A Pletscher; G Bartholini
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

View more
  4 in total

1.  An analysis of the peripheral effects of l-DOPA on autonomic nerve function.

Authors:  M J Antonaccio; R D Robson
Journal:  Br J Pharmacol       Date:  1974-09       Impact factor: 8.739

Review 2.  Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism.

Authors:  R M Pinder; R N Brogden; P R Sawyer; T M Speight; G S Avery
Journal:  Drugs       Date:  1976       Impact factor: 9.546

3.  The cardiovascular effects of L-dopa in the pithed rat.

Authors:  E Eden; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1974-08       Impact factor: 8.739

4.  Gastrin release by bombesin in the dog.

Authors:  G Bertaccini; V Erspamer; P Melchiorri; N Sopranzi
Journal:  Br J Pharmacol       Date:  1974-10       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.